Antitrust Antitrust

Drug companies queried by US appeals court on practicality of individual suits in appeal of Zetia buyers' class certification

By Khushita Vasant
  • 06 May 2021 17:41
  • 06 May 2021 19:48
Counsel for drug companies disputing a lower court order certifying a class of direct purchasers of the drug Zetia were asked today by US appeals court judges to explain their argument that the claims don't qualify for class treatment and explain why the 35-member class shouldn't have been certified.

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Khushita Vasant

Chief Antitrust Correspondent, US

Khushita covers US antitrust enforcement and litigation for MLex. A former Brussels hand, she wrote about about antitrust & mergers for the Policy and Regulatory Report (PaRR), she has covered the EU's actions against Google, Apple, Facebook and Amazon to name a few. Khushita specialises in tech and patent policy coverage which featured in the Concurrences Antitrust Writing Awards. Previously as a financial journalist for The Wall Street Journal and Dow Jones Newswires, she wrote about monetary policy and the bond and currency markets. Khushita studied journalism at Mumbai University, and received an Erasmus Mundus scholarship for a masters from universities in Germany and Austria.

Discover MLex

Stay on top of global regulatory developments

Latest News